Evidence map›Paper›PMID 18366613›Full record

ArticleBMC genomics2008

A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions.

Jack Y Yang, Mary Qu Yang, Zuojie Luo, Yan Ma, Jianling Li, Youping Deng, Xudong Huang

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC genomics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Optical sorting: past, present and future.Light, science & applications · 2025
    Review
  3. Article
  4. Article
  5. A survey on automated wheeze detection systems for asthmatic patients.Bosnian journal of basic medical sciences · 2012
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Jack Y YangDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. jyang@bwh.harvard.edu
Mary Qu Yang
Zuojie Luo
Yan Ma
Jianling Li
Youping Deng
Xudong Huang
First Affiliated Hospital of GuangXi Medical University · CNBrigham and Women's Hospital · USHarvard University · USNational Institutes of Health · USUniversity of Southern Mississippi · US

Funding

Nanoneurotoxicity of Metal Oxide Nanomaterials and NeurodegenerationR01AG056614 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HUANG, XUDONG · 2017 to 2020
$1.5M
6 · The paper itself

Abstract

backgroundThe prognosis for many cancers could be improved dramatically if they could be detected while still at the microscopic disease stage. It follows from a comprehensive statistical analysis that a number of antigens such as hTERT, PCNA and Ki-67 can be considered as cancer markers, while another set of antigens such as P27KIP1 and FHIT are possible markers for normal tissue. Because more than one marker must be considered to obtain a classification of cancer or no cancer, and if cancer, to classify it as malignant, borderline, or benign, we must develop an intelligent decision system that can fullfill such an unmet medical need.

resultsWe have developed an intelligent decision system using machine learning techniques and markers to characterize tissue as cancerous, non-cancerous or borderline. The system incorporates learning techniques such as variants of support vector machines, neural networks, decision trees, self-organizing feature maps (SOFM) and recursive maximum contrast trees (RMCT). These variants and algorithms we have developed, tend to detect microscopic pathological changes based on features derived from gene expression levels and metabolic profiles. We have also used immunohistochemistry techniques to measure the gene expression profiles from a number of antigens such as cyclin E, P27KIP1, FHIT, Ki-67, PCNA, Bax, Bcl-2, P53, Fas, FasL and hTERT in several particular types of neuroendocrine tumors such as pheochromocytomas, paragangliomas, and the adrenocortical carcinomas (ACC), adenomas (ACA), and hyperplasia (ACH) involved with Cushing's syndrome. We provided statistical evidence that higher expression levels of hTERT, PCNA and Ki-67 etc. are associated with a higher risk that the tumors are malignant or borderline as opposed to benign. We also investigated whether higher expression levels of P27KIP1 and FHIT, etc., are associated with a decreased risk of adrenomedullary tumors. While no significant difference was found between cell-arrest antigens such as P27KIP1 for malignant, borderline, and benign tumors, there was a significant difference between expression levels of such antigens in normal adrenal medulla samples and in adrenomedullary tumors.

conclusionsOur frame work focused on not only different classification schemes and feature selection algorithms, but also ensemble methods such as boosting and bagging in an effort to improve upon the accuracy of the individual classifiers. It is evident that when all sorts of machine learning and statistically learning techniques are combined appropriately into one integrated intelligent medical decision system, the prediction power can be enhanced significantly. This research has many potential applications; it might provide an alternative diagnostic tool and a better understanding of the mechanisms involved in malignant transformation as well as information that is useful for treatment planning and cancer prevention.

Indexed as

AlgorithmsArtificial IntelligenceAdrenal Cortex NeoplasmsBiomarkers, TumorChinaCushing SyndromeGene Expression ProfilingHumansImmunohistochemistryIn Situ HybridizationLogistic ModelsProliferating Cell Nuclear AntigenReverse Transcriptase Polymerase Chain ReactionBiomarkers, TumorProliferating Cell Nuclear Antigen

Identifiers

PMID18366613
PMCPMC2386065
OpenAlexW1995056942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.